High-Intensity Focused Ultrasound (HIFU) Treatment for Prostate Cancer: HIFU Treatment for Prostate Cancer

Rüştü Türkay

doi:10.70087/rami.tui/010108

Authors

Rüştü Türkay, Associate Prof. Dr. Department of Radiology, Haseki Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye Author https://orcid.org/0000-0002-7837-9861

DOI:

https://doi.org/10.70087/rami.tui/010108

Keywords:

prostat cancer, prostat imaging, HIFU

Abstract

High-Intensity Focused Ultrasound (HIFU) represents an emerging minimally invasive treatment modality for prostate cancer. This technology employs focused ultrasound waves to ablate prostate tissue, offering a precise and targeted strategy for the management of localized prostate cancer. The present paper aims to deliver a comprehensive review of HIFU, encompassing its technology, advantages, risks, patient selection criteria, and post-treatment monitoring.

Downloads

Download data is not yet available.

References

American Cancer Society. Key Statistics for Prostate Cancer. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics. Published 2020. Updated daily. Accessed January 19, 2024.

Gelet A, Chapelon JY, Bouvier R, Souchon R, Pangaud C, Abdelrahim AF, et al. Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol. 1996;29(2):174-83.

Hopstaken JS, Bomers JGR, Sedelaar MJP, Valerio M, Fütterer JJ, Rovers MM. An updated systematic review on focal therapy in localized prostate cancer: What has changed over the past 5 years? Eur Urol. 2022 Jan;81(1):5-33. doi: 10.1016/j.eururo.2021.08.005.

Uchida T, Sanghvi NT, Gardner TA, Koch MO, Ishii D, Minei S, et al. Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report. Urology. 2002 Mar;59(3):394-398; discussion 398-9. doi: 10.1016/s0090-4295(01)01624-7.

Ganzer R, Arthanareeswaran VKA, Ahmed HU, Cestari A, Rischmann P, Salomon G, et al. Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology (ESUT) position statement. Prostate Cancer Prostatic Dis. 2018 Jun;21(2):175-86. doi: 10.1038/s41391-018-0042-0.

Crouzet S, Chapelon JY, Rouvière O, Mege-Lechevallier F, Colombel M, Tonoli-Catez H, et al. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol. 2014 May;65(5):907-14. doi: 0.1016/j.eururo.2013.04.039.

Rebillard X, Gelet A, Davin JL, Soulie M, Prapotnich D, Cathelineau X, Rozet F, Vallancien G. Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer. J Endourol. 2005 JulAug;19(6):693-701. doi: 10.1089/end.2005.19.693.

Ghai S, Finelli A, Corr K, Chan R, Jokhu S, Li X, et al. MRI-guided focused ultrasound ablation for localized intermediate-risk prostate cancer: Early results of a phase II trial. Radiology. 2021 Mar;298(3):695-703. doi: 10.1148/radiol.2021202717.

Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. PROMIS study group. Diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017 Feb 25;389(10071):815-22. doi: 10.1016/S0140-6736(16)32401-1.

Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.JAMA. 2015 Jan 27;313(4):390-7. doi: 10.1001/jama.2014.17942.

Bakavicius A, Marra G, Macek P, Robertson C, Abreu AL, George AK, et al. Available evidence on HIFU for focal treatment of prostate cancer: a systematic review. Int Braz J Urol. 2022 Mar-Apr;48(2):263-74. doi: 10.1590/S1677-5538.IBJU.2021.0091.

Napoli A, Alfieri G, Scipione R, Leonardi A, Fierro D, Panebianco V, et al. High-intensity focused ultrasound for prostate cancer. Expert Rev Med Devices. 2020 May;17(5):427-33. doi: 10.1080/17434440.2020.1755258.

Chapelon JY, Rouvière O, Crouzet S, Gelet A. Prostate-focused ultrasound therapy. Adv Exp Med Biol. 2016;880:21-41. doi: 10.1007/978-3-319-22536-4_2.

Rébillard X, Davin JL, Soulié M; Comité de Cancérologie de l’Association Française d’Urologie. Traitement par HIFU du cancer de la prostate: revue de la littérature et indications de traitement [Treatment by HIFU of prostate cancer: survey of literature and treatment indications]. Prog Urol. 2003 Dec;13(6):1428-56.

Turkbey B, Pinto PA, Choyke PL. Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol. 2009 Apr;6(4):191- 203. doi: 10.1038/nrurol.2009.27.

Ziglioli F, Baciarello M, Maspero G, Bellini V, Bocchialini T, Cavalieri D, et al. Oncologic outcome, side effects and comorbidity of high-intensity focused ultrasound (HIFU) for localized prostate cancer. A review. Ann Med Surg (Lond). 2020 May 30;56:110-5. doi: 10.1016/j.amsu.2020.05.029.

Ayerra Perez H, Barba Abad JF, Extramiana Cameno J. An update on focal therapy for prostate cancer. Clin Genitourin Cancer. 2023 Dec;21(6):712.e1-712.e8. doi: 10.1016/j.clgc.2023.04.013.

Siedek F, Yeo SY, Heijman E, Grinstein O, Bratke G, Heneweer C, et al. Magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU): Technical background and overview of current clinical applications (Part 1). Rofo. 2019 Jun;191(6):522-30. English. doi: 10.1055/a-0817-5645.

Duwe G, Boehm K, Haack M, Sparwasser P, Brandt MP, Mager R, et al. Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected. World J Urol. 2023 May;41(5):1293-9. doi: 10.1007/s00345-023-04352-9.

Hectors SJ, Jacobs I, Moonen CT, Strijkers GJ, Nicolay K. MRI methods for the evaluation of high-intensity focused ultrasound tumor treatment: Current status and future needs. Magn Reson Med. 2016 Jan;75(1):302-7. doi: 10.1002/mrm.25758.

Khandwala YS, Morisetty S, Ghanouni P, Fan RE, Soerensen SJC, Rusu M, et al. Evaluation of post-ablation mpMRI as a predictor of residual prostate cancer after focal high intensity focused ultrasound (HIFU) ablation. Urol Oncol. 2022 Nov;40(11):489.e9-489.e17. doi: 10.1016/j.urolonc.2022.07.017.

Apfelbeck M, Chaloupka M, Schlenker B, Stief CG, Clevert DA. Follow-up after focal therapy of the prostate with high-intensity focused ultrasound (HIFU) using contrast-enhanced ultrasound (CEUS) in combination with MRI image fusion. Clin Hemorheol Microcirc. 2019;73(1):135-43. doi: 10.3233/CH-199222.

Bründl J, Osberghaus V, Zeman F, Breyer J, Ganzer R, Blana A, et al. Oncological long-term outcome after whole-gland high-intensity focused ultrasound for prostate cancer-21-yr follow-up. Eur Urol Focus. 2022 Jan;8(1):134-40. doi: 10.1016/j.euf.2020.12.016.

Rouvière O, Gelet A, Crouzet S, Chapelon JY. Prostate focused ultrasound focal therapy--imaging for the future. Nat Rev Clin Oncol. 2012 Dec;9(12):721-7. doi: 10.1038/nrclinonc.2012.136.

Chen FK, de Castro Abreu AL, Palmer SL. Utility of ultrasound in the diagnosis, treatment, and follow-up of prostate cancer: State of the art. J Nucl Med. 2016 Oct;57(Suppl 3):13S-18S. doi: 10.2967/jnumed.116.177196.